The Future of Oral Therapeutics: Global Macromolecule Formulation Market Estimated at USD 29.5 million by 2033: Persistence Market Research
August 02, 2023 13:27 ET
|
Persistence Market Research
New York, Aug. 02, 2023 (GLOBE NEWSWIRE) -- The global oral macromolecule formulation market is expected to grow at a CAGR of 5.0% from 2022 to 2033. The global oral macromolecule formulation market...
Syneos Health Stockholders Approve Agreement with Private Investment Consortium
August 02, 2023 08:47 ET
|
Syneos Health, Inc.
MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today...
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
July 31, 2023 17:05 ET
|
Affimed N.V.
Stable disease was observed in three out of seven heavily pretreated patientsNo dose-limiting toxicities or unexpected toxicities were observed HEIDELBERG, Germany, July 31, 2023 (GLOBE NEWSWIRE)...
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
July 28, 2023 08:00 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company...
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
July 24, 2023 08:00 ET
|
PaxMedica, Inc.
The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing an NDA for the use of PAX-101 (intravenous...
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
July 24, 2023 07:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage...
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)
July 10, 2023 08:00 ET
|
Biodexa Pharmaceuticals PLC
10 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in theTreatment of Children with Newly Diagnosed Diffuse Midline Gliomas...
Results of Appeal of Delisting Determination
July 06, 2023 16:30 ET
|
Biodexa Pharmaceuticals PLC
6 July 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Results of Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical...
Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)
July 06, 2023 08:15 ET
|
Biodexa Pharmaceuticals PLC
6 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) Biodexa Pharmaceuticals PLC...
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
July 06, 2023 08:00 ET
|
PaxMedica, Inc.
· Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years · VoxNova will be responsible for physician registration, safety monitoring and reimbursement for treatment, as...